The Number of Risk Factors Determines the Outcome Of Stage II Colorectal Cancer Patients

被引:4
作者
Lin, Hung-Hsin [1 ]
Yang, Hsueh-Li [1 ]
Lin, Jen-Kou [1 ]
Lin, Chun-Chi [1 ]
Wang, Huann-Sheng [1 ]
Yang, Shung-Haur [1 ]
Jiang, Jeng-Kai [1 ]
Lan, Yuan-Tzu [1 ]
Lin, Tzu-Chen [1 ]
Chen, Wei-Shone [1 ]
Liang, Wen-Yih [2 ]
Chang, Shih-Ching [1 ]
机构
[1] Natl Yang Ming Univ, Taipei Vet Gen Hosp, Dept Surg, Div Colon & Rectal Surg, Taipei 11217, Taiwan
[2] Natl Yang Ming Univ, Taipei Vet Gen Hosp, Dept Pathol, Taipei 11217, Taiwan
关键词
colon cancer; risk factor; outcome; stage II; LYMPH-NODE EVALUATION; COLON-CANCER; ADJUVANT THERAPY; FLUOROURACIL; POPULATION; SURVIVAL; SURGERY; ADENOCARCINOMA; LEVAMISOLE; ONTARIO;
D O I
10.5754/hge13189
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: We evaluated the prognostic significance of clinicopathologic features recommended by the majority of guidelines for identifying high-risk stage II colon cancer patients. Methodology: We enrolled 665 stage II colorectal cancer patients at Taipei Veterans General Hospital in 2002-2006. Patients who received preoperative or postoperative chemotherapy were excluded (124). The measured endpoint was disease-free survival.Results: Of 541 patients, 59 showed stage T4 tumors; 35, lymphovascular invasion; 19, poor differentiation, and 251, carcinoembryonic antigen levels of >5 ng/mL; 53 underwent emergent operations. Colorectal cancer recurred in 84 patients. The 5-year disease-free survival rate was 84.5%. Univariate and multivariate analyses revealed 3 independent factors affecting the prognosis significantly tumor stage T4, high carcinoembryonic antigen level, and presence of lymphovascular invasion. Considering the cumulative effect of risk factors, the 5-year disease-free survival rate of patients with tumors without any risk factor was 90.2%, which was significantly better than that of patients with 1 or 2 risk factors (82.3%, 61.6%).Conclusions: Stage II colorectal cancer patients had excellent outcome. Adjuvant chemotherapy may be warranted for patients with multiple risk factors.
引用
收藏
页码:1024 / 1027
页数:4
相关论文
共 25 条
[1]   Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].
Andre, T ;
Boni, C ;
Mounedji-Boudiaf, L ;
Navarro, M ;
Tabernero, J ;
Hickish, T ;
Topham, C ;
Zaninelli, M ;
Clingan, P ;
Bridgewater, J ;
Tabah-Fisch, I ;
de Gramont, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351
[2]  
Andre Thierry, 2004, Clin Colorectal Cancer, V4 Suppl 1, pS22
[3]  
[Anonymous], 2007, CANC REG ANN REP
[4]   Lymph node evaluation in colorectal cancer patients: A population-based study [J].
Baxter, NN ;
Virnig, DJ ;
Rothenberger, DA ;
Morris, AM ;
Jessurun, J ;
Virnig, BA .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (03) :219-225
[5]   American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer [J].
Benson, AB ;
Schrag, D ;
Somerfield, MR ;
Cohen, AM ;
Figueredo, AT ;
Flynn, PJ ;
Krzyzanowska, MK ;
Maroun, J ;
McAllister, P ;
Van Cutsem, E ;
Brouwers, M ;
Charette, M ;
Haller, DG .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) :3408-3419
[6]  
Berger AC, 2004, AM SURGEON, V70, P235
[7]   Lymph node counts, rates of positive lymph nodes, and patient survival for colon cancer surgery in Ontario, Canada: A population-based study [J].
Bui, L ;
Rempel, E ;
Reeson, D ;
Simunovic, M .
JOURNAL OF SURGICAL ONCOLOGY, 2006, 93 (06) :439-445
[8]   Lymph node evaluation and survival after curative resection of colon cancer: Systematic review [J].
Chang, George J. ;
Rodriguez-Bigas, Miguel A. ;
Skibber, John M. ;
Moyer, Virginia A. .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (06) :433-441
[9]   Obstruction and perforation in colorectal adenocarcinoma: An analysis of prognosis and current trends [J].
Chen, HS ;
Sheen-Chen, SM .
SURGERY, 2000, 127 (04) :370-376
[10]  
Compton CC, 2000, ARCH PATHOL LAB MED, V124, P979